GLOW

The combination has never been studied, so it is graded D. On their own, GHK-Cu is graded C (cosmetic research) / D (other), BPC-157 C and TB-500 D.

Strengths: 50 / 10 / 10 mg (70 mg total)
Also known as: GHK-Cu / BPC-157 / TB-500 blend
Contains: GHK-Cu, BPC-157, TB-500
Molecule: Blend of three peptides, 5:1:1 by mass (GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg)

Origin

A research vial combining a copper peptide (GHK-Cu), known from skin creams, with BPC-157 and TB-500, two peptides studied mostly in animals for tissue repair. 'GLOW' is a community stack name; the components span skin research and tissue-repair research.

How it works

GHK binds copper very tightly and is studied in skin and wound biology; BPC-157 and TB-500 are studied in animal tissue-repair models. The fixed 5:1:1 ratio means the vial holds five times more GHK-Cu by mass than either other peptide. Whether copper redistributes among the peptides or speeds their breakdown in solution is unknown.

What the research shows

No study in people has tested this mix, and GHK-Cu has no human data outside topical products. GHK-Cu's human data are topical (skin creams, a hair spray), BPC-157's are tiny and uncontrolled, and TB-500 has none. GHK-Cu alone showed no detectable breakdown over 14 days at 60 °C, with oxidation the most damaging condition. No published study was found on GHK-Cu mixed with BPC-157 or TB-500, so stability of the three together is unknown.

Key studies

Mortazavi et al., BioImpacts 2025 GHK-Cu stable alone in solution at pH 5.5–7.4; oxidizing conditions most damaging.
FDA PCAC Briefing Document, BPC-157, 2026 Adverse-event report of recurring skin and gum darkening from a BPC-157/TB-500 blend.

Safety findings

Clinicians have reported raised liver enzymes and copper levels in some people using non-topical GHK-Cu products outside studies, and copper excess is a particular concern in copper-handling disorders such as Wilson disease. An FDA adverse-event case of recurring skin darkening came from a BPC-157/TB-500 blend, and a third peptide makes attribution harder. All three components show pro-repair, blood-vessel or cell-migration effects in lab models.

Regulatory status

No component is an approved drug; GHK-Cu is legal in cosmetics with appearance-only claims. Topical GHK-Cu is in 503A Category 1 and GHK-Cu is reportedly scheduled for FDA advisory committee review by early 2027, but injectable GHK-Cu, BPC-157 and TB-500 have no compounding pathway. WADA prohibits BPC-157 (S0) and TB-500 (S2) at all times; GHK-Cu is not named.

Catalog notes

Offered as 50/10/10 mg of GHK-Cu, BPC-157 and TB-500 (70 mg total). Current lot GLOW70-0803 has a certificate (COA7598, August 17, 2026): 99.80% combined purity, endotoxin <0.05 EU/mL and heavy metals <0.01 ppm, with no sterility result listed. Check the lot's certificate for the exact molecular weights (reference sources list 889 g/mol for TB-500); follow the storage stated on the label and certificate. The catalog notes the powder should be blue.

In kits: Glow Bundle